Exagen Inc. to Participate in the 2022 KeyBanc Capital Markets Life Sciences and MedTech Investor Forum
March 09 2022 - 4:05PM
Exagen Inc. (Nasdaq: XGN), a leading provider of
autoimmune testing solutions, today announced its participation in
the KeyBanc Capital Markets Life Sciences and MedTech Investor
Forum, which takes place March 22-23, 2022. Ron Rocca, Exagen’s
President and Chief Executive Officer, and Kamal Adawi, Exagen’s
Chief Financial Officer, will participate in a virtual fireside
chat on Wednesday, March 23rd at 3:45 PM ET. Interested parties may
access the live webcast of the fireside chat using a link on
Exagen’s website at investors.exagen.com/events.
About Exagen Inc.
Exagen is dedicated to transforming the care
continuum for patients suffering from debilitating and chronic
autoimmune diseases by enabling timely differential diagnosis and
optimizing therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand, several of which are based on our proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable providers to improve care for patients
through the differential diagnosis, prognosis and monitoring of
complex autoimmune and autoimmune-related diseases, including
rheumatoid arthritis and lupus. For further information please
visit www.exagen.com.
Forward Looking Statements
Exagen cautions you that statements in this press
release regarding matters that are not historical facts are
forward-looking statements. These statements are based on Exagen's
current beliefs and expectations. The inclusion of forward-looking
statements should not be regarded as a representation by Exagen
that any of its plans will be achieved. Actual results may differ
from those set forth in this press release due to the risks and
uncertainties inherent in Exagen’s business, including, without
limitation: the COVID-19 pandemic may continue to adversely affect
Exagen’s business, financial condition and results of operations,
including as a result of shutdowns of its facilities and operations
as well as those of its suppliers and courier services, impeding
patient movement and interruptions to healthcare services causing a
decrease in test volumes, disruptions to the supply chain of
material needed for its tests, its sales and commercialization
activities and its ability to receive specimens and perform or
deliver the results from its tests, and delays in ongoing and
planned clinical trials involving its tests; Exagen’s commercial
success depends upon attaining and maintaining significant market
acceptance of its testing products and promoted therapeutics among
rheumatologists, patients, third-party payors and others in the
medical community; Exagen’s ability to successfully execute on its
business strategies; third party payors not providing coverage and
adequate reimbursement for Exagen’s testing products or promoted
therapeutics; Exagen’s ability to obtain and maintain intellectual
property protection for its testing products; regulatory
developments affecting Exagen’s business; and other risks described
in Exagen’s prior press releases and Exagen’s filings with the
Securities and Exchange Commission (SEC), including under the
heading “Risk Factors” in Exagen’s Annual Report on Form 10-K for
the year ended December 31, 2020 and any subsequent filings with
the SEC. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and Exagen undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement, which is made under the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995.
Investor RelationsExagen Inc. Ryan
Douglasrdouglas@exagen.com 760.560.1525
CompanyExagen Inc.Kamal Adawi,
Chief Financial
Officerkadawi@exagen.com
760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Apr 2023 to Apr 2024